Ascendis Pharma A/S (NASDAQ:ASND) to Post FY2024 Earnings of ($6.59) Per Share, Cantor Fitzgerald Forecasts

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for Ascendis Pharma A/S in a note issued to investors on Wednesday, September 4th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biotechnology company will earn ($6.59) per share for the year, down from their previous forecast of ($4.00). Cantor Fitzgerald currently has a "Overweight" rating and a $170.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($5.60) per share.

Several other research analysts also recently commented on ASND. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a "buy" rating in a report on Tuesday, August 13th. Bank of America boosted their price target on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a "buy" rating in a research note on Wednesday. TD Cowen reduced their price objective on Ascendis Pharma A/S from $175.00 to $157.00 and set a "buy" rating on the stock in a research report on Wednesday. Citigroup lowered their price target on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, JPMorgan Chase & Co. lowered their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an "overweight" rating for the company in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $187.08.

Ascendis Pharma A/S Stock Up 0.1 %

ASND traded up $0.15 on Friday, hitting $119.15. The company's stock had a trading volume of 625,893 shares, compared to its average volume of 393,567. The firm has a market cap of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63. Ascendis Pharma A/S has a 12 month low of $85.29 and a 12 month high of $161.00. The company's 50 day simple moving average is $134.38 and its 200-day simple moving average is $138.20.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently added to or reduced their stakes in the stock. Gilbert & Cook Inc. raised its holdings in shares of Ascendis Pharma A/S by 8.4% during the 4th quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company's stock worth $357,000 after acquiring an additional 220 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $1,681,000. Massachusetts Financial Services Co. MA grew its stake in Ascendis Pharma A/S by 20.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company's stock worth $191,346,000 after purchasing an additional 254,749 shares in the last quarter. First Turn Management LLC purchased a new position in Ascendis Pharma A/S during the 4th quarter worth $19,092,000. Finally, Quadrant Capital Group LLC lifted its stake in Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 151 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.